Phlebofa, tablets 600 mg 30 pcs

Pharmacotherapeutic group: Angioprotective agent.

TATX code: C05SA03

Pharmacological properties

Pharmacodynamics

. Diosmin belongs to the group of bioflavonoids and has phlebotonic properties (it reduces stretching of veins, increases venous tone (dose-dependent effect), reduces venous congestion), improves lymphatic drainage (it increases tone and frequency of contraction of lymphatic capillaries, increases their functional density, It reduces the lymphatic pressure), improves microcirculation (it increases capillary resistance (dose-dependent effect) and decreases their permeability), reduces leucocyte adhesion to the venous wall and their migration into the paravenous tissue, improves oxygen diffusion and perfusion in the skin tissue and has an anti-inflammatory effect. It enhances the vasoconstrictor effect of adrenaline and noradrenaline, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.

Pharmacokinetics

Diosmin is rapidly absorbed from the gastrointestinal tract. It is detected in blood plasma 2 hours after intake. The bioavailability of the drug after oral administration is approximately 40 – 57.9%. Part of the drug is metabolized by cecum bacteria to form hippuric and benzoic acids. Maximum concentration in blood plasma is reached 5 hours after intake. The drug accumulates in all layers of the wall of the hollow veins and subcutaneous veins of the lower limbs, to a lesser extent in the kidneys, liver and lungs and other tissues. Distribution volume of the drug is 62.1 l. The maximum selective accumulation of diosmin and/or its metabolites in the wall of the venous vessels is noted 9 hours after administration and persists for 96 hours.

Diosmin is rapidly metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid. Metabolites of diosmin excreted mainly by the kidneys in the form of conjugates with glucuronic acid. 79% of ingested diosmin is excreted by the kidneys, 11% – the intestines, 2.4% – with the bile. Enterohepatic circulation of the drug is noted. After taking diosmin labeled with radioactive isotope about 86% of the drug is excreted by the kidneys and intestines within 48 hours.

Indications

Varicose veins of the lower extremities (elimination of symptoms);
chronic lymphovenous insufficiency of the lower extremities (elimination of symptoms);
acute hemorrhoids (in complex therapy to relieve symptoms);
microcirculation disorders (for example, with idiopathic edema).

Pharmacological effect

Pharmacotherapeutic group: Angioprotective agent.

ATX code: C05CA03

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Diosmin belongs to the group of bioflavonoids, has a phlebotonic effect (reduces the distensibility of veins, increases the tone of the veins (dose-dependent effect), reduces venous stagnation), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases the resistance of capillaries (dose-dependent effect), reduces their permeability), reduces the adhesion of leukocytes to the venous wall and their migration into paravenous tissues, improves oxygen diffusion and perfusion in the skin tissue, and has an anti-inflammatory effect. Strengthens the vasoconstrictor effect of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.

Pharmacokinetics

Diosmin is quickly absorbed from the gastrointestinal tract. Detected in blood plasma 2 hours after administration. The bioavailability of the drug after oral administration is approximately 40 – 57.9%. Part of the drug is metabolized by bacteria of the cecum with the formation of hippuric and benzoic acids. The maximum concentration in blood plasma is achieved 5 hours after administration. The drug accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities, to a lesser extent in the kidneys, liver and lungs and other tissues. The volume of distribution of the drug is 62.1 l. The maximum selective accumulation of diosmin and/or its metabolites in the wall of venous vessels is observed 9 hours after administration and persists for 96 hours.

Diosmin is rapidly metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid. Diosmin metabolites are excreted primarily by the kidneys in the form of conjugates with glucuronic acid. 79% of taken diosmin is excreted by the kidneys, 11% by the intestines, and 2.4% by the bile. Enterohepatic circulation of the drug is noted. After taking radiolabeled diosmin, approximately 86% of the drug is excreted by the kidneys and intestines within 48 hours.

Special instructions

Treatment of acute hemorrhoids is carried out in combination with other drugs. If there is no rapid clinical effect, it is recommended to consult with a proctologist, if necessary, conduct additional examination and adjust the therapy.

In case of venous circulation disorders (varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities), the maximum treatment effect is ensured by a combination of therapy with lifestyle changes: it is advisable to avoid prolonged stay in an upright position and reduce excess body weight. In some cases, wearing special stockings (compression stockings) helps improve blood circulation.

There is insufficient experience with the use of diosmin in children under 18 years of age. If there is no improvement or if the symptoms of the disease worsen, consult a doctor! Do not exceed the maximum duration and recommended doses of the drug without consulting your doctor!

Impact on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Diosmin

Composition

1 tablet contains:

Active substance:

diosmin 600 mg;

Excipients:

gelatin 50 mg,

sodium carboxymethyl starch 40 mg,

magnesium stearate 10 mg,

microcrystalline cellulose up to 1000 mg.

Contraindications

Hypersensitivity to the components of the drug;
children under 18 years of age (experience of use is limited);
pregnancy (first trimester) and lactation (experience of use is limited).

Side Effects

The frequency of side effects is determined in accordance with the WHO classification of adverse drug reactions by frequency of occurrence: very often – more than 1/10, often – more than 1/100 and less than 1/10, infrequently – more than 1/1000 and less than 1/100, rarely – more than 1/10000 and less than 1/1000, very rarely – less than 1/10000, including isolated cases; unknown frequency (it is impossible to determine the frequency of occurrence of an adverse reaction based on the available data).

From the gastrointestinal tract: often – nausea, vomiting, diarrhea (diarrhea), dyspeptic disorders, heartburn, constipation; infrequently – colitis.

From the central nervous system: rarely – headache, dizziness.

From the skin and subcutaneous fat, rarely – skin rashes, itching;

Allergic reactions: rarely – urticaria, unknown frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema (Quincke’s edema).

General disorders: rarely – malaise.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Clinically significant interactions of diosmin with other drugs have not been described.

Overdose

Cases of overdose have not been described. Given the wide therapeutic range of diosmin, the risk of intoxication in case of overdose appears to be negligible. A specific antidote is unknown. In case of overdose of the drug, seek medical help immediately!

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

Ozon, Russia